Tocilizumab treatment for new onset refractory status epilepticus
Tocilizumab treatment for new onset refractory status epilepticus
复制标题
DOI：
10.1002/ana.25374
复制
发表时间：
2018-12-01
影响因子：
11.2
通讯作者：
Lee, Sang Kun
中科院分区：
文献类型：
--
作者：
Jun, Jin-Sun;Lee, Soon-Tae;Lee, Sang Kun
我们研究了白细胞介素 6 受体抑制剂托珠单抗对 7 名新发难治性癫痫持续状态 (NORSE) 患者的治疗潜力，这些患者对使用利妥昔单抗 (n = 5) 或不使用利妥昔单抗 (n = 2) 的常规免疫疗法仍然难以治疗。 6 名患者在接受 1 或 2 剂托珠单抗治疗后，癫痫持续状态 (SE) 终止，中位间隔为 3 天。观察期间他们没有再出现SE。然而，2 名患者在托珠单抗治疗期间出现了与感染相关的严重不良事件。需要进一步的前瞻性对照研究来验证托珠单抗在 NORSE 患者中的有效性和安全性。
We investigated the therapeutic potential of the interleukin-6 receptor inhibitor tocilizumab in 7 patients with new onset refractory status epilepticus (NORSE) who remained refractory to conventional immunotherapy with rituximab (n = 5) or without rituximab (n = 2). Status epilepticus (SE) was terminated after 1 or 2 doses of tocilizumab in 6 patients with a median interval of 3 days from the initiation. They had no recurrence of SE during the observation. However, 2 patients experienced severe adverse events related to infection during the tocilizumab therapy. Further prospective controlled studies are warranted to validate the efficacy and safety of tocilizumab in patients with NORSE.